tiprankstipranks
Catalyst Pharma (DE:CN2)
FRANKFURT:CN2

Catalyst Pharma Stock Analysis & Ratings

0 Followers

CN2 Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range― - ―
Previous Close€12.93
Volume0.00
Average Volume (3M)658.00
Market CapN/A
Enterprise ValueN/A
P/E RatioN/A
Beta0.83
Next EarningsNov 09, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score10
EPS (TTM)N/A
Shares Outstanding102,780,151
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. Volume163
30 Day Avg. Volume658
P/B Ratio4.67
P/S Ratio8.78
P/CF Ratio16.70
P/FCF Ratio20.90
Total Debt€29.00K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside28.17% Upside
Rating ConsensusStrong Buy
AlphaN/A
Number of Analyst Covering4


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

CN2 FAQ

What was Catalyst Pharma’s price range in the past 12 months?
Currently, no data Available
What is Catalyst Pharma’s market cap?
Currently, no data Available
What is Catalyst Pharma’s price target?
The average price target for Catalyst Pharma is €16.57. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is €17.55 ,the lowest forecast is €15.60. The average price target represents 28.17% Increase from the current price of €12.93.
    What do analysts say about Catalyst Pharma?
    Catalyst Pharma’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
      When is Catalyst Pharma’s upcoming earnings report date?
      Catalyst Pharma’s upcoming earnings report date is Nov 09, 2022 which is in 86 days.
        How were Catalyst Pharma’s earnings last quarter?
        Catalyst Pharma released its earnings results on Aug 09, 2022. The company reported €0.195 earnings per share for the quarter, beating the consensus estimate of €0.166 by €0.029.
          Is Catalyst Pharma overvalued?
          According to Wall Street analysts Catalyst Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Catalyst Pharma pay dividends?
            Catalyst Pharma does not currently pay dividends.
            What is Catalyst Pharma’s EPS estimate?
            Catalyst Pharma’s EPS estimate is €0.19.
              How many shares outstanding does Catalyst Pharma have?
              Currently, no data Available
              What happened to Catalyst Pharma’s price movement after its last earnings report?
              Catalyst Pharma reported an EPS of €0.195 in its last earnings report, beating expectations of €0.166. Following the earnings report the stock price went up 3.955%.
                Which hedge fund is a major shareholder of Catalyst Pharma?
                Among the largest hedge funds holding Catalyst Pharma’s share is Royce & Associates LLC. It holds Catalyst Pharma’s shares valued at 15M.

                  ---

                  Catalyst Pharma Stock Analysis

                  Smart ScoreOutperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  10

                  Analyst Forecast

                  Strong Buy
                  Average Price Target: €16.57

                  Blogger Sentiment

                  Bullish
                  DE:CN2 Sentiment 100% Sector Average 70%

                  Insider Transactions

                  ▼ Sold Shares
                  Worth $318.5K over the Last 3 Months

                  News Sentiment

                  Positive
                  Bullish 100% Bearish 0%

                  Technicals

                  SMA
                  Positive
                  20 days / 200 days
                  Momentum
                  132.83%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  25.35%
                  Trailing 12-Months
                  Asset Growth
                  27.82%
                  Trailing 12-Months
                  The Catalyst Pharma Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Catalyst Pharma

                  Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasmsThe company was founded Huckel E. Hubert in January 2002 and is headquartered in Coral Gables, FL.

                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AbbVie
                  Amgen
                  Gilead Sciences
                  Moderna
                  Vertex Pharmaceuticals

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis